An Open Label Study to Establish the Preferred Dose and to Assess Safety and Overall Response Rate of Avastin in Combination With Concomitant Thoracic Radiation and Chemotherapy (Cisplatin and Etoposide) in Locally Advanced Unresectable Non-squamous Non-small Cell Lung Cancer.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Dose limiting toxicity
Throughout Study
No
Clinical Trials
Study Director
Hoffmann-La Roche
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
BO21563
NCT00776698
April 2009
February 2010
Name | Location |
---|